Clinical trial · Interventional
Pemetrexed in Patients With Advanced Neuroendocrine Tumors
A Phase II Study of Pemetrexed in Patients With Advanced Neuroendocrine Tumors
NCT00424723CI-TRIAL-00003785completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to find out what effects (good and bad) pemetrexed has on patients with advanced neuroendocrine tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neuroendocrine Tumors | Neuroendocrine Tumor | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pemetrexed | Drug | Pemetrexed | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To assess the radiologic response rate associated with pemetrexed in patients with neuroendocrine tumors.
- timeFrame
- 2 years
Secondary outcomes (3)
- measure
- To perform an analysis of the biochemical response rate
- timeFrame
- 2 years
- measure
- to assess the toxicity associated with pemetrexed
- timeFrame
- 2 years
- measure
- and to assess the progression-free and overall survival of patients.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Metastatic or locally unresectable neuroendocrine tumor, excluding small cell carcinoma * Measurable tumor * 18 year of age or older * ECOG performance status of 0,1 or 2 * Life expectancy of greater than 12 weeks * WBC: \> 3.0/mm3 * Plts: \> 100,000/mm3 * Bilirubin: \< 2.0 mg/dl * AST \< 3 x ULN (except in patients with known hepatic metastases wherein SST may be \< 5 x ULN) * Neutrophils \> 1000/mm3 * Creatinine Clearance \> 45 ml/min. Should be measured using the standard Cockroft-Gault formula Exclusion Criteria: * Prior treatment with pemetrexed * Clinically apparent central nervous system metastases or carcinomatous meningitis * Myocardial infarction in the past 6 months * Major surgery in the past two weeks * Uncontrolled serious medical or psychiatric illness * Pregnant or lactating women
References
Publications (1)
- RESULTChan JA, Zhu AX, Stuart K, Bhargava P, Earle CC, Clark JW, Casey C, Regan E, Kulke MH. Phase II study of pemetrexed in patients with advanced neuroendocrine tumors. Cancer Chemother Pharmacol. 2010 Oct;66(5):961-8. doi: 10.1007/s00280-010-1248-6. Epub 2010 Feb 4. PMID 20130879